Switching to camizestrant, a next-generation oral SERD, significantly prolongs progression-free survival and maintains ...

Discover how breast cancer precision oncology using a combination therapy improves survival in advanced PIK3CA-mutated cases.

Positive results from the SERENA-6 Phase III trial have shown that AstraZeneca’s camizestrant alongside a cyclin-dependent ...

A new triple therapy for aggressive, advanced breast cancer slows the progression of the disease, delays the need for further ...

A NEW triple threat drug combination could hold aggressive breast cancer at bay for an extra year, a trial found. Adding the ...

Clinical outcome of Russian HER2-positive breast cancer patients with brain metastases: Retrospective review. This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I. This abstract does ...

Final OS results from INAVO120 show inavolisib plus palbociclib and fulvestrant significantly improves survival, delays ...

The Phase III trial showed that the new targeted therapy, inavolisib (Itovebi), provides significant survival benefits for ...

A new triple-drug treatment for aggressive advanced breast cancer can cut deaths by a third, a major trial has found.

The treatment could also delay the need for gruelling chemotherapy, according to the trial. | ITV National News ...

The lead author said the study also showed the inavolisib-based therapy "more than doubled the time before their cancer progressed or worsened".